Paritaprevir(Veruprevir ABT-450),1216941-48-8

体外研究：

Paritaprevir inhibits p-glycoprotein (p-gp) in vitro. ABT-450 is an efficacious inhibitor of HCV NS3/4A protease, with 50% effective concentration values of 1.0, 0.21, 5.3, 19, 0.09, and 0.69 nM against stable HCV replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and 6a, respectively. The CC50 of ABT-450 is more than 37 μM, resulting in an in vitro selectivity index of ≥37,000-fold. ABT-450 demonstrates activity across multiple HCV genotypes, with an EC50 of 5.3 nM against the genotype 2a JFH-1 subgenomic replicon.

体内研究：After oral administration, paritaprevir reaches maximum concentrations in a mean of 4-5 h with increases in exposure more than dose proportional. Absolute bioavailability is about 50% after administering with food. It displays high (about 97-99.9 %) plasma protein binding and has apparent volumes of distribution of 16.7L. Paritaprevir metabolism occurs via CYP3A4 (predominantly) and CYP3A5.

产品信息订购：

公告提醒：爱必信所有产品和服务仅用于科学研究，不用于临床应用及其他用途提供产品和服务（也不为任何个人提供产品和服务）!   YZ剂描述： 产品名称：Paritaprevir(Veruprevir ABT-450) 产品别名：ABT-450,ABT450，ABT 450 英文别名：ABT-450;ABT450;ABT 450 靶点：HCV genotype 1b ,HCV genotype 1a CAS：1216941-48-8 纯度：>98% 外观：Powder 保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. 描述：NS3/4A protease inhibitor 溶解性：
体外	DMSO	100 mg/mL(130.56 mM)

产品货号	产品名称	规格	价格	大包装及货期
abs814120	Paritaprevir(Veruprevir ABT-450)	100mg	18900	立即咨询

产品更多信息请进入爱必信网站咨询